Oral Semaglutide
4 articles on Oral Semaglutide, written by Shotlee and medically reviewed for clinical accuracy.
Eli Lilly's Orforglipron: More Effective GLP-1 Pill for Weight Loss?
Eli Lilly's investigational GLP-1 pill, orforglipron, demonstrated greater weight loss and blood sugar control than oral semaglutide in a major phase 3 trial for type 2 diabetes. Patients lost 6-8% body weight compared to 4-5%, though with higher GI side effects. This could signal a shift toward more effective oral therapies.
6 min read
Study Flags Gut Risks from SNAC in Oral Weight-Loss Pills
A groundbreaking study from Adelaide University is raising questions about SNAC, the ingredient making oral weight-loss drugs like semaglutide tablets viable. In a 21-day animal model, repeated SNAC exposure linked to lower beneficial gut bacteria, reduced protective compounds, and elevated inflammation markers. As tablet versions gain popularity, experts call for more research on this component's full impact.
6 min read
Oral GLP-1s Benefit HF Patients: SOUL Trial Subanalysis
A subanalysis of the SOUL trial reveals that once-daily oral semaglutide (Rybelsus) lowers the risk of heart failure hospitalization, urgent visits, or CV death by 22% in patients with HF, diabetes, and ASCVD or CKD. Those with preserved ejection fraction (HFpEF) saw even greater protection at 41%. Experts highlight this as a key option for frail patients avoiding injections.
6 min read
Oral Wegovy: Benefits, Dosing, and What Patients Need to Know
Novo Nordisk's oral Wegovy has launched with impressive prescription volumes, offering a pill alternative to injections for weight management. Learn about its efficacy, ideal candidates, dosing, and how it fits into GLP-1 therapy. This guide breaks down the science and practical advice for patients.
5 min read